Recent trends in (under)treatment of hypercholesterolaemia in the Netherlands

被引:7
作者
Mantel-Teeuwisse, AK
Verschuren, WMM
Klungel, OH
de Boer, A
Kromhout, D
机构
[1] Univ Utrecht, UIPS, Dept Pharmacoepidemiol & Pharmacotherapy, NL-3508 TB Utrecht, Netherlands
[2] Natl Inst Publ Hlth & Environm, Ctr Prevent & Hlth Serv Res, NL-3720 BA Bilthoven, Netherlands
[3] Natl Inst Publ Hlth & Environm, Nutr & Consumer Safety Div, NL-3720 BA Bilthoven, Netherlands
关键词
antilipaemic agents; cardiovascular diseases; drug therapy; hypercholesterolaemia;
D O I
10.1111/j.1365-2125.2004.02152.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aim To assess recent trends in undertreatment of hypercholesterolaemia (1998-2002). Methods Data were obtained from the third cross-sectional examination of the Monitoring Project on Risk Factors for Chronic Diseases (n = 4878; age 31-70 years), conducted in the Netherlands. Treatment eligibility was established according to Dutch guidelines. Data from the second examination (1993-1997) were used to assess time trends. The association between demographic variables, cardiovascular disease risk factors, drug use and lipid-lowering medication was assessed using multivariable logistic regression. Results Overall, 45.9%[95% confidence interval (CI) 41.4, 50.4] of respondents eligible for treatment were treated, and 17.4% (95% CI 13.9, 20.9) were both treated and controlled (1998-2002). Treatment increased significantly after 1995, showed a slight decrease in subsequent years until 2000, when treatment increased again. Subgroups less frequently treated for primary prevention included among others males [odds ratio (OR) = 0.08; 95% CI 0.03, 0.21], younger patients (OR = 0.93 per year; 95% CI 0.88, 0.98), diabetics (OR = 0.19; 95% CI 0.07, 0.56), untreated hypertensives (OR = 0.21; 95% CI 0.09, 0.49) and current smokers (OR = 0.09; 95% CI 0.03, 0.25). In secondary prevention, patients with a history of stroke were less likely to receive treatment (OR = 0.41; 95% CI 0.18, 0.94) compared with patients with a history of ischaemic heart disease. Conclusions Treatment of hypercholesterolaemia has steadily increased over the past 10 years in the Netherlands. However, at present still less than one out of two eligible for treatment is treated, and only about one out of six is both treated and controlled.
引用
收藏
页码:310 / 316
页数:7
相关论文
共 25 条
[1]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497
[2]  
Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3
[3]   Mortality risk reduction associated with smoking cessation in patients with coronary heart disease - A systematic review [J].
Critchley, JA ;
Capewell, S .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (01) :86-97
[4]   Is cholesterol a risk factor for stroke?: Yes [J].
Demchuk, AM ;
Hess, DC ;
Brass, LM ;
Yatsu, FM .
ARCHIVES OF NEUROLOGY, 1999, 56 (12) :1518-1520
[5]   Evolution of statin prescribing 1994-2001: a case of agism but not of sexism? [J].
DeWilde, S ;
Carey, IM ;
Bremner, SA ;
Richards, N ;
Hilton, SR ;
Cook, DG .
HEART, 2003, 89 (04) :417-421
[6]   Growth in use of statins after trials is not targeted to most appropriate patients [J].
Feely, T ;
McGettigan, P ;
Kelly, A .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 67 (04) :438-441
[7]   Serum total cholesterol concentrations and awareness, treatment, and control of hypercholesterolemia among US adults - Findings from the National Health and Nutrition Examination Survey, 1999 to 2000 [J].
Ford, ES ;
Mokdad, AH ;
Giles, WH ;
Mensah, GA .
CIRCULATION, 2003, 107 (17) :2185-2189
[8]   Lipid-lowering drugs and risk of myopathy:: A population based follow-up study [J].
Gaist, D ;
Rodríguez, LAG ;
Huerta, C ;
Hallas, J ;
Sindrup, SH .
EPIDEMIOLOGY, 2001, 12 (05) :565-569
[9]   Cross sectional survey of effectiveness of lipid lowering drugs in reducing serum cholesterol concentration in patients in 17 general practices [J].
Hippisley-Cox, J ;
Cater, R ;
Pringle, M ;
Coupland, C .
BMJ-BRITISH MEDICAL JOURNAL, 2003, 326 (7391) :689-692
[10]  
Jukema JW, 1999, ACTA CARDIOL, V54, P163